
Opinion|Videos|September 18, 2024
Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
Medical experts compare the efficacy and safety of new therapies, including FTD/TPI plus bevacizumab and fruquintinib, to regorafenib for metastatic colorectal cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How do these new therapy options (FTD/TPI plus bevacizumab, fruquintinib) compare with regorafenib in terms of efficacy and safety?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement
Trending on AJMC
1
Four Ways to Boost Awareness, Access for COVID-19 PEP
2
Health Equity & Access Weekly Roundup: November 20, 2026
3
Value-Based Pilot for Medicaid Members With Substance Use Disorder
4
Acne Treatment Adherence Ranges From 6% to 84% in Real-World Studies
5

